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SUMMARY AND GENERAL DISCUSSION
All scientific work is incomplete - whether it be observational or experimental. 
All scientific work is liable to be upset or modified by advancing knowledge. 
That does not confer upon us a freedom to ignore the knowledge we already have or 
postpone the action that it appears to demand at a given time.
- Sir Austin Bradford Hill
The aim of the research in this thesis was to provide evidence that further contributes 
towards the prevention and management of hypertensive disorders of pregnancy. As low 
dose aspirin use and calcium supplementation lower the risk of hypertensive disorders of 
pregnancy, proper screening and selection of women who may benefit is of paramount 
importance. Although with this their prevalence may diminish, hypertensive disorders of 
pregnancy will nevertheless continue to complicate pregnancies. When they do, proper 
management that targets optimal maternal and neonatal outcomes requires timely delivery 
that is evidence based, a foundation towards which this thesis aimed to contribute.
Risk factors, old and new
Chapters 2 and 3 describe studies of a population-based Dutch cohort that assessed different 
risk factors for pre-eclampsia and delivery of a small for gestational age (SGA) infant. The 
linked design of the cohort dataset in these studies allowed for the evaluation of clinical risk 
factors present in the first pregnancy and their effect on second pregnancy risks. 
Chapter 2 describes why maximum diastolic arterial blood pressure values in the first 
pregnancy should be considered as a novel risk factor for the risk of pre-eclampsia in a 
subsequent pregnancy and provides further evidence for history of pre-eclampsia as the 
main risk factor for recurrence. In women that did not present with pre-eclampsia in the 
first pregnancy, increased values of maximum diastolic blood pressure showed a direct 
relationship with increased risk of pre-eclampsia. 
Chapter 3 shows that delivery of an SGA infant increases the risk of pre-eclampsia in the 
following pregnancy and vice-versa, but this is limited to specific situations. In the absence 
of hypertensive disorders in the first pregnancy, SGA delivery slightly increased the risk of 
pre-eclampsia in the subsequent pregnancy, but the absolute risk remained lower than one 
percent. In the presence of hypertensive disorders, SGA delivery did not further impose 
additional pre-eclampsia risk. Similarly, while late onset pre-eclampsia slightly increased 
SGA risk, the increased risks associated with early onset pre-eclampsia were of the same 
order of magnitude of those associated with preterm delivery.
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Who is actually at risk?
Together, Chapters 2 and 3 serve as examples of the importance of careful evaluation of 
the different risk factors through multivariable models. Although numerous risk factors for 
hypertensive disorders of pregnancy have been well established in the literature, efforts to 
systematically evaluate, quantify their relative importance and tease out confounders have 
been scarce.1 This is made clear by the lack of consensus over who are the women that 
should be considered at high-risk of developing hypertensive disorders of pregnancy as the 
World Health Organization (WHO), the International Society for the Study of Hypertension 
in Pregnancy (ISSHP), the British National Institute of Clinical Excellence (NICE), and the US 
Preventive Services Task Force (USPSTF) all differ in their screening recommendations.2–5 
Further reflecting the absence of systematic assessment, while the first two provide only a 
single list of “established strong clinical risk factors”, the latter two distinguish between high 
and moderate risk factors — although still with discordances.
The checklist method
Collecting different clinical risk factors in a checklist is one approach to determine who is at 
risk. The relative merit of this approach is found in its simplicity, especially in settings that 
do not allow for more rigor. In a randomized trial that evaluated folic acid for the prevention 
of pre-eclampsia in Argentina, Jamaica, Canada, Australia, and the United Kingdom, women 
were selected to participate through a simple screening process such as this. Women with 
pre-existing hypertension, pre-pregnancy diabetes (type 1 or 2), pre-eclampsia in a previous 
pregnancy, body mass index (BMI) over or equal 35 kg/m2, or with a twin pregnancy were 
considered at high-risk for pre-eclampsia and included in the trial. This simple screening 
procedure resulted in incidences of 14.8% and 13.5% of pre-eclampsia in each arm of 
the trial, 3 to 4 times the usual estimated prevalence, although still undoubtedly highly 
unespecific.6–8
Biomarkers in prediction models 
In addition to clinical risk factors, the use of biomarkers such as serum placental growth 
factor (PlGF) and serum pregnancy-associated plasma protein-A (PAPP-A) has been proposed 
to augment the screening for individual risk. A 2017 prospective multicenter study of 8775 
pregnant women compared the screening performance of the 2010 NICE and the 2013 
American College of Obstetricians and Gynecologists (ACOG) guidelines to the proposed 
screening algorithm by the Fetal Medicine Foundation (FMF), which includes the use of 
biomarkers. 4,9–11 Detections rates of delivery with pre-eclampsia at less than 32, 37 and over 
or equal to 37 weeks of gestation for the algorithm were 100%, 75% and 43%, respectively, 
with a 10% false positive rate. The corresponding rates using the NICE screening were 41%, 
39% and 34% with the same rate of false positives. The 2013 ACOG screening had high 
detection rates, respectively 94%, 90% and 89%, although at the cost of a false positive rate 
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of 64.2%. Along with the inclusion of additional predictive factors, the superior performance 
of the FMF algorithm is justified by use of a multivariable model opposed to the simple 
checking of a risk factor list.
Aspirin in all pregnancies?
The implications of the use of an early version of this algorithm to screen for high-risk of 
hypertensive disorders of pregnancy and consequently select women who may benefit 
from low dose aspirin were studied by an Irish group in a cost-effectiveness analysis that 
compared it to a policy of routine aspirin use. 12 The inclusion of not only biomarkers, but 
also of the ultrasonographic uterine artery pulsatility index in the screening algorithm 
increases its cost. As a result, the authors concluded that routine aspirin use was the optimal 
cost-effective approach under a variety of assumptions. Next to routine low dose aspirin 
use, they also concluded that the least cost-ineffective screening was based not on history 
and clinical characteristics of the mother, but only on the mean arterial blood pressure. 
The authors did not include in their analysis the potential effects of low dose aspirin on 
spontaneous preterm birth and SGA prevention.13,14 If these were to be taken into account 
and excluding known contraindications, a future case for aspirin in all pregnancies could 
certainly be made. This may be especially relevant in developing countries, where women 
are particularly vulnerable to high morbidity and mortality in complicated pregnancies and 
a low-cost intervention such as aspirin could be reasonably implemented.
The same Irish group also performed a feasibility three-armed open label randomized trial 
with 564 nulliparous women who did not meet NICE criteria for aspirin use in pregnancy that 
compared (1) no aspirin use to (2) FMF screening and to (3) routine aspirin use. Adherence 
to aspirin use was good at 90% but routine aspirin use more than doubled rates of post-
partum hemorrhage over 500 ml (13.5% vs. 5.6%). This was a surprising finding as it conflicts 
with previous pooled results from nine trials including 22,760 women that evaluated aspirin 
use and revealed no evidence for increased risk of post-partum hemorrhage (relative risk 
1.02; 95% confidence interval 0.96–1.09).15,16
Folic acid as a reference model
Although ineffective in the prevention of pre-eclampsia, folic acid has been shown to 
reduce the risk of neural tube defects in large randomized trials and its supplementation is 
recommended worldwide before conception and during the first trimester of pregnancy. 17–19 
In 2014, analysis of a population-based cohort in the UK showed that this recommendation 
has had relative success as in 84.5% of 108,525 pregnancies folic acid was used, although 
only in 25.5% it was introduced preconceptionally.20
Lest the repetition of the thalidomide-induced teratogenesis disaster, the safety profile of a 
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supplement or drug is the most critical aspect for the introduction of a policy for its use in 
every pregnancy.21 Potential harms of folic acid supplementation were reviewed in 2018 by 
the US Preventive Services Task Force (USPSTF) and their conclusion was that the risks “from 
folic acid supplementation taken at the usual doses are no greater than small”. Although 
aspirin long term use in the context of cardiovascular disease has been extensively studied, 
before a policy of low dose aspirin in every pregnancy can be safely adopted, similar efforts 
to clarify short and long-term effects of its use during pregnancy need to occur. 22 The variety 
of responses from different healthcare providers towards the adoption of such a policy also 
needs to be taken into account. Issues such as home birth provide a colorful example of 
heated debate over the medicalization of birth.23,24
Rather than a policy of routine low dose aspirin use, a two-stage screening process is more 
likely to be implemented in the near future. This is supported by findings of secondary 
analysis of data from the ASPRE trial. This study screened 34,573 women for preterm 
pre-eclampsia, the hypertensive disorder of pregnancy with the strongest evidence for its 
prevention with aspirin. Preterm pre-eclampsia in this study was presented by 239 (0.7%) 
women. The ACOG criteria for aspirin introduction were fulfilled by 22,287 (64.5%) women 
and preterm pre-eclampsia incidence in this group was 0.97% (223 women). A second 
stage of screening through FMF criteria resulted in an incidence of 4.8% for those screened 
positive and only 0.25% for those screened negatively. Similarly, of the 1392 women who 
met NICE high-risk criteria, 5.17% presented preterm pre-eclampsia and application of 
FMF criteria in these women resulted in incidences of 8.7% and 0.7% for those screened 
positively and negatively, respectively. If on one hand ACOG criteria are overinclusive, the 
application of NICE high and moderate risk criteria missed 126 (52.7%) presentations of 
preterm pre-eclampsia.
However unlikely in the short term, even if at some point in the future a policy of routine 
aspirin use becomes norm, women at high-risk for hypertensive disorders of pregnancy 
will still benefit from proper monitoring and will need to be referred to and cared for in 
specialized services. Because of this, the screening challenge imposed by instruments 
that are too unspecific, not sensitive enough or too expensive provides an opportunity for 
considering the prediction potential of novel risk factors and reevaluation of well-known 
candidates. It is in this context that the results discussed in Chapters 2 and 3 are found. 
Until 2019, the NICE guideline is the only one so far to include hypertension in a previous 
pregnancy as a risk factor for pre-eclampsia. Chapter 2 findings largely substantiate this 
recommendation and further suggest that the development of screening models that 
include different levels of maximum diastolic pressure in a previous pregnancy as a risk 
factor may allow for more nuanced evaluation of individual risk.
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In the same manner, chapter 3 findings offer support for SGA as a mild to moderate risk 
factor for pre-eclampsia. The findings also make clear the notion that the presence of 
simultaneous risk factors, in this case SGA delivery and hypertension, do not necessarily 
imply increased pre-eclampsia risk to a subsequent pregnancy beyond that imposed by each 
risk factor alone.  This latter finding may be justified by their common pathophysiological 
pathway which brings forth the presentation of one, the other or of both complications. The 
specific phenotypical presentation then influenced by the presence of both known factors, 
such as chronic hypertension, obesity, smoking, and other unknown predisposing factors 
based on the genetic, environmental and behavioral make-up of the woman.
Immediate delivery versus expectant management
Chapter 4 explored the challenges of randomized controlled trials (RCTs) aimed at the study 
of rare outcomes in a heterogeneous population through the obstetric lens of the immediate 
delivery versus expectant management dilemma for women at or near term presenting with 
hypertensive disorders of pregnancy. To overcome these challenges, the realization of an 
individual participant data meta-analysis (IPDMA) was proposed. This came to fruition in the 
study described in Chapter 5¸ an IPDMA that included women from five RCTs to strengthen 
the evidence base in the management of hypertensive disorders of pregnancy. Although 
immediate delivery was shown to reduce the risk of a composite of HELLP syndrome and 
eclampsia, the adverse consequences of an early birth as demonstrated by increased rates 
of respiratory distress syndrome (RDS) are clear. A policy of delivery at 37 weeks of gestation 
for women presenting with pre-eclampsia without severe features appears to strike a fair 
balance between maternal and neonatal risks. It is still unclear though if that is still the case 
in gestational hypertension and in women with chronic hypertension.
The challenge of rare outcomes
This latter finding illustrates how difficult the study of rare outcomes is in randomized 
controlled trials and two possible pragmatic solutions: the use of surrogate and composite 
outcomes. The authors of the DIGITAT and HYPITAT-I trials chose umbilical arterial pH as a 
secondary outcome and as a component of the primary composite neonatal outcome to act 
as a surrogate for rare outcomes.  In this case, the associated rare outcomes were neonatal 
mortality, hypoxic ischemic encephalopathy, intraventricular hemorrhage, periventricular 
leucomalacia, and cerebral palsy.28,29 It is because of this association and not because of the 
occurrence of the surrogate per se that it represents an outcome to be avoided.
In a similar manner, progression to severe hypertension (systolic blood pressure of 170 mm 
Hg or higher or diastolic blood pressure of 110 mm Hg or higher) was included in HYPITAT-I 
as a component of the primary composite maternal outcome. The interpretation of the 
less frequent occurrence of this composite outcome in women who were randomized to 
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delivery was subject to criticism at the time of the publication of the trial in 2009. The use 
of progression to severe hypertensive disease, the most common adverse outcome and 
responsible for the majority of the effect found in the trial, as a surrogate for severe maternal 
morbidity such as cerebrovascular accidents was considered insufficient to justify delivery 
“in otherwise well women”. 30–32 Despite this, it is clear that the information provided by 
surrogate outcomes in feasible trials is nonetheless preferable to a choice of complete 
uncertainty regarding management and their impact on rare outcomes. This is especially 
the case as data generated in such trials is candidate for use in meta-analysis such as we 
have described in Chapter 5.  
Composite outcomes
The inclusion of progression to severe hypertension in the HYPITAT-I trial composite 
maternal outcome along with maternal mortality and severe maternal morbidity such as 
eclampsia and HELLP syndrome fails in three out of three criteria designed to help clinicians 
interpret results of trials with composite outcomes.33 These outcomes do not have the 
same importance to patients, do not occur with a similar frequency and do not likely have 
similar relative risk reductions. The potential drive to design a trial with a high likelihood of 
a positive result, as well as the degree this may affect publication potential in high impact 
journals and change clinical practice also needs to be taken into account in an evaluation 
like this.34–36
The composite maternal outcome in the HYPITAT-II trial was a step forward to correct 
for these potential issues with the exclusion of progression to severe hypertension as a 
component. The proposal for an IPDMA described in Chapter 4 followed a similar strategy. 
In the IPDMA prospective PROSPERO registration, described in Chapter 5, we took a further 
step to align our outcomes with the previously mentioned criteria and restricted the primary 
maternal composite outcome to the occurrence of eclampsia, HELLP syndrome or both 
while maintaining the previous composite as a secondary outcome.  
Heterogeneous populations
While in the Netherlands the HYPITAT-I trial resulted in an increase in induction of labor rates 
in women with both pre-eclampsia and gestational hypertension at term, the UK National 
Institute for Health and Clinical Excellence (NICE) guideline was also changed to reflect 
the findings. NICE, however, limited the indication of immediate delivery to only women 
with pre-eclampsia at term. It was argued that the trial was unable to show significant 
reduction of progression to severe disease for women with gestational hypertension at 
term. 4,37 The American College of Obstetricians and Gynecologists (ACOG) on the other 
hand recommends delivery upon diagnosis of pre-eclampsia and gestational hypertension 
at or beyond 37 weeks of gestation.
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The differences in policy proposed by these institutions may reflect not only alternative 
viewpoints regarding the available data, but also how specific findings are to be applied 
to the populations of these different countries that may by themselves be also highly 
heterogeneous. Ethnic, cultural, institutional, environmental, and genetic factors of each 
population all have impact on how the benefits and harms of particular policies may actually 
come to fruition.
Caesar’s dilemma
While Chapter 5 had a wider scope, Chapter 6 focused on the specific population of women 
presenting with unripe cervixes in pregnancies complicated by hypertensive disorders or 
suspected intrauterine growth restriction. For this group of women, it was still unclear 
whether induction of labor at term increased cesarean section and adverse neonatal 
outcome rates when compared to expectant management. These rates were shown to 
be comparable and induction of labor resulted in a lower number of infants presenting 
umbilical arterial pH < 7.05.
These findings, published in 2016, joined a mass of published evidence that could put to 
rest the long-standing debate over increased cesarean section rates after induction of labor, 
even in the case of immature cervixes in women presenting with complicated pregnancies. 
Nonetheless, the classic textbook Williams Obstetrics in its revised 2018 edition starts 
its discussion of labor induction risk by listing cesarean sections first among other 
complications: chorioamnionitis, uterine rupture, and postpartum hemorrhage. Of these, 
a two to threefold greater risk for cesarean delivery after induction of labor is emphasized 
based on studies published in 2003.38
Nevertheless, the textbook authors found room to also include a mention to evidence 
from 2009 that — as Chapter 6 does — puts this assessment into question. In particular a 
mention was made for the, at the time, upcoming results of the ARRIVE trial, still ongoing at 
the time of the revision of the book. Published in 2018, the ARRIVE trial randomized 6,106 
low-risk nulliparous women at 38 weeks of gestation to induction of labor at 39 weeks or 
expectant management.39 The results show no difference in adverse neonatal outcomes 
and a lower cesarean section rate in the induction of labor group. Based on these findings, 
The Society for Maternal-Fetal Medicine (SMFM) revised its recommendations in the same 
year,  advising care providers to only offer elective induction of labor at 39 weeks for low risk 
nulliparous women that met ARRIVE eligibility criteria.40
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On the other hand, it is curious to find an apparent reversal of ARRIVE’s findings in a paper 
by Carmichael et al. The authors state that “it would be helpful to know whether the 
increased occurrence of cesarean birth in the women in the IOL group was attributable to 
the increased incidence of hypertensive disorders”. As Carmichael et al. did not reverse the 
results of the trial in the rest of their paper, this could maybe represent a degree of cognitive 
dissonance in face of findings that contradict long held beliefs, but most definitely a failure 




The inertia inherent to health care provides a formidable challenge to the exciting and 
around-the-corner future promised by machine learning applied to Big Data. Despite initial 
mixed results showing that there is still a lot of work ahead, electronic health records fed 
by real time data collected by personal electronic devices provide previously unforeseen 
opportunities for individualized, timely and effective care.42,43 It is almost certain that 
approaches such as those found in Chapters 2 and 3 will in a not too distant future be 
substituted by national or even international registries that are automatically updated, open 
to real time access and ready to feed up-to-date AI models that will immensely enhance 
clinical practice.
This will provide ample opportunity for the evaluation of individual risk factors, prescription 
of appropriate interventions when necessary and prompt immediate action on the 
occurrence of adverse effects and complications. With the slow pace of health care change 
this could merely be wishful thinking, but the rates at which new technologies have been 
adopted in recent years suggest that uptake may be faster than expected (Figure 1).44
Figure 1. Uptake of technology in US households between 1920 and 2019 (Source: Our World in Data 
(https://ourworldindata.org/).
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In a similar way but on a more limited scale, Chapters 5 and 6 provide examples of the 
benefit of aggregating data from different sources to arrive at clinically relevant findings. 
Undoubtedly, different and more sophisticated approaches could have been taken in both 
cases. In Chapter 5, regression and time-to-event based analyses could have possibly 
elucidated remaining questions regarding the appropriate timing of delivery for certain 
subgroups of women such as those that present with non-severe gestational hypertension 
rather than pre-eclampsia. Such analyses nonetheless impose additional challenges in terms 
of technical implementation and plain viability as outcomes remain rare despite increased 
sample sizes. Further addition of data from the PHOENIX and WILL trials will again provide 
opportunities for such approaches to be taken. 
Improved methods, new data, and more interdisciplinary collaboration will allow for new 
insights to arise and targeted answers to be found. Whether the overall messages in this 
thesis will remain largely unchanged or be significantly altered is unclear, although my bias 




1.  Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in 
early pregnancy: systematic review and meta-analysis of large cohort studies. Bmj. 2016:i1753. 
doi:10.1136/bmj.i1753.
2.  Gülmezoglu AM, Souza JP. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia 
and Eclampsia.; 2011.
3.  Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, 
Ishaku S. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management 
Recommendations for International Practice. Hypertens (Dallas, Tex  1979). 2018;72(1):24-43. 
doi:10.1161/HYPERTENSIONAHA.117.10803.
4.  National Collaborating Center for Women’s and Chidren. Hypertension in pregnancy : the 
management of hypertensive disorders during pregnancy the management of hypertensive 
disorders. R Coll Obstet Gynaecol. 2011;107(August):47.
5.  LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: 
U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819-
826. doi:10.7326/M14-1884.
6.  Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive 
disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391-403. doi:10.1016/j.
bpobgyn.2011.01.006.
7.  Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and 
eclampsia: A systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7. doi:10.1016/j.
ejogrb.2013.05.005.
8.  Wen SW, White RR, Rybak N, Gaudet LM, Robson S, Hague W, Simms-Stewart D, Carroli G, Smith 
G, Fraser WD, Wells G, Davidge ST, Kingdom J, Coyle D, Fergusson D, Corsi DJ, Champagne J, Sabri 
E, Ramsay T, Mol BWJ, Oudijk MA, Walker MC. Effect of high dose folic acid supplementation in 
pregnancy on pre-eclampsia (FACT): Double blind, phase III, randomised controlled, international, 
multicentre trial. BMJ. 2018;362:1-8. doi:10.1136/bmj.k3478.
9.  Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. 2013;122(5):1122-1131.
10.  O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks 
model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. 
Am J Obstet Gynecol. 2016;214(1):103.e1-103.e12. doi:10.1016/j.ajog.2015.08.034.
11.  O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, Carbone IF, Dutemeyer 
V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos 
A, Plasencia W, Nicolaides KH. Multicenter screening for pre-eclampsia by maternal factors 
and biomarkers at 11–13 weeks’ gestation: comparison with NICE guidelines and ACOG 
recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756-760. doi:10.1002/uog.17455.
12.  Mone F, O’Mahony JF, Tyrrell E, Mulcahy C, McParland P, Breathnach F, Morrison JJ, Higgins J, Daly S, 
Cotter A, Hunter A, Dicker P, Tully E, Malone FD, Normand C, McAuliffe FM. Preeclampsia Prevention 
Using Routine Versus Screening Test–Indicated Aspirin in Low-Risk Women. Hypertension. 2018:1. 
doi:10.1161/HYPERTENSIONAHA.118.11718.
13.  Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is 
associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol. 
2018;219(4):399.e1-399.e6. doi:10.1016/j.ajog.2018.06.011.
137
Summary, general discussion and perspectives
7
14.  Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the 
prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am 
J Obstet Gynecol. 2017;216(2):110-120.e6. doi:10.1016/j.ajog.2016.09.076.
15.  Mone F, Mulcahy C, McParland P, Breathnach F, Downey P, McCormack D, Culliton M, Stanton A, 
Cody F, Morrison JJ, Daly S, Higgins J, Cotter A, Hunter A, Tully EC, Dicker P, Alfirevic Z, Malone FD, 
McAuliffe FM. Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening 
Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised 
controlled trial. BMJ Open. 2018;8(7):e022056. doi:10.1136/bmjopen-2018-022056.
16.  Gyamfi-Bannerman C, Manuck T. Low-Dose Aspirin Use During Pregnancy. ACOG Comm Opin 743. 
2018;132(1):44-52.
17.  Wen SW, White RR, Rybak N, Gaudet LM, Robson S, Hague W, Simms-Stewart D, Carroli G, Smith 
G, Fraser WD, Wells G, Davidge ST, Kingdom J, Coyle D, Fergusson D, Corsi DJ, Champagne J, Sabri 
E, Ramsay T, Mol BWJ, Oudijk MA, Walker MC. Effect of high dose folic acid supplementation in 
pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, 
multicentre trial. BMJ. 2018;362:k3478. doi:10.1136/bmj.k3478.
18.  Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional 
vitamin supplementation. N Engl J Med. 1992;327(26):1832-1835. doi:10.1056/
NEJM199212243272602.
19.  Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC 
Vitamin Study Research Group. Lancet (London, England). 1991;338(8760):131-137.
20.  Hodgetts VA, Morris RK, Francis A, Gardosi J, Ismail KM. Effectiveness of folic acid supplementation 
in pregnancy on reducing the risk of  small-for-gestational age neonates: a population study, 
systematic review and meta-analysis. BJOG. 2015;122(4):478-490. doi:10.1111/1471-0528.13202.
21.  Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C 
Embryo Today. 2015;105(2):140-156. doi:10.1002/bdrc.21096.
22.  Garcia Rodriguez LA, Martin-Perez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding Risk 
with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS One. 
2016;11(8):e0160046. doi:10.1371/journal.pone.0160046.
23.  Committee Opinion No. 697: Planned Home Birth. Obstet Gynecol. 2017;129(4):e117-e122. 
doi:10.1097/AOG.0000000000002024.
24.  Shaw JCA. The Medicalization of Birth and Midwifery as Resistance. Health Care Women Int. 
2013;34(6):522-536. doi:10.1080/07399332.2012.736569.
25.  Chen Y, Zhao D, Wang B, Zhu J, Zhang J, Zhang Y. Association of intrauterine exposure to aspirin and 
blood pressure at 7 years of age: a secondary analysis. BJOG An Int J Obstet Gynaecol. 2018:1-9. 
doi:10.1111/1471-0528.15561.
26.  Parchem JG, Sibai BM. An aspirin a day in pregnancy keeps childhood hypertension away? BJOG. 
February 2019. doi:10.1111/1471-0528.15598.
27.  Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, Thilaganathan B, Boyd HA. Risk 
of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: 
nationwide cohort study. BMJ. 2017;358:j3078. doi:10.1136/bmj.j3078.
28.  Malin GL, Morris RK, Khan KS. Strength of association between umbilical cord pH and perinatal 
and long term outcomes: systematic review and meta-analysis. BMJ. 2010;340:c1471-c1471. 
doi:10.1136/bmj.c1471.
29.  Yeh P, Emary K, Impey L. The relationship between umbilical cord arterial pH and serious adverse 




30.  Cunningham FG. Severe preeclampsia and eclampsia: Systolic hypertension is also important. 
Obstet Gynecol. 2005;105(2):237-238. doi:10.1097/01.AOG.0000153144.05885.fa.
31.  Martin JN, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and 
eclampsia: A paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246-
254. doi:10.1097/01.AOG.0000151116.84113.56.
32.  Bewley S, Shennan A. HYPITAT and the fallacy of pregnancy interruption. Lancet. 2010;375(9709):119. 
doi:10.1016/S0140-6736(10)60043-8.
33.  Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant 
D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, Wu P, Schünemann HJ, Jaeschke R, Guyatt GH. 
Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594 LP-596. doi:10.1136/
bmj.330.7491.594.
34.  Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman 
GH. The uncertainty principle and industry-sponsored research. Lancet (London, England). 
2000;356(9230):635-638. doi:10.1016/S0140-6736(00)02605-2.
35.  Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant 
trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260. doi:10.1056/
NEJMsa065779.
36.  Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to 
statistical significance or direction  of trial results. Cochrane database Syst Rev. 2009;(1):MR000006. 
doi:10.1002/14651858.MR000006.pub3.
37.  Van Der Tuuk K, Koopmans CM, Groen H, Mol BW, Van Pampus MG. Impact of the HYPITAT trial on 
doctors’ behaviour and prevalence of eclampsia in the Netherlands. BJOG An Int J Obstet Gynaecol. 
2011;118(13):1658-1660. doi:10.1111/j.1471-0528.2011.03138.x.
38.  Cunningham FG, Leveno KJ, Hoffman BL, Bloom SL, Spong CY. Williams Obstetrics.; 2018.
39.  Payne B a, Hutcheon J a, Ansermino JM, Hall DR, Bhutta Z a, Bhutta SZ, Biryabarema C, Grobman 
W a, Groen H, Haniff F, Li J, Magee L a, Merialdi M, Nakimuli A, Qu Z, Sikandar R, Sass N, Sawchuck 
D, Steyn DW, Widmer M, Zhou J, von Dadelszen P. A risk prediction model for the assessment 
and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the 
miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. 
PLoS Med. 2014;11(1):e1001589. doi:10.1371/journal.pmed.1001589.
40.  SMFM Statement on Elective Induction of Labor in Low-Risk Nulliparous Women at Term: the 
ARRIVE Trial. Am J Obstet Gynecol. 2019;221(1):B2-B4. doi:10.1016/j.ajog.2018.08.009.
41.  Carmichael SL, Snowden JM. The ARRIVE Trial: Interpretation from an Epidemiologic Perspective. J 
Midwifery Womens Health. July 2019. doi:10.1111/jmwh.12996.
42.  Ryu B, Kim N, Heo E, Yoo S, Lee K, Hwang H, Kim J-W, Kim Y, Lee J, Jung SY. Impact of an 
Electronic Health Record-Integrated Personal Health Record on Patient Participation in Health 
Care: Development and Randomized Controlled Trial of MyHealthKeeper. J Med Internet Res. 
2017;19(12):e401-e401. doi:10.2196/jmir.8867.
43.  Jakicic JM, Davis KK, Rogers RJ, King WC, Marcus MD, Helsel D, Rickman AD, Wahed AS, Belle SH. 
Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss: 
The IDEA Randomized Clinical Trial. JAMA. 2016;316(11):1161-1171. doi:10.1001/jama.2016.12858.
44.  Ritchie A, Roser M. Technology Adoption. https://ourworldindata.org/technology-adoption. 
Published 2019.
139
7
